Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

NCT ID: NCT04483531

Last Updated: 2024-03-07

Basic Information

• Recruitment Status: APPROVED_FOR_MARKETING
• Study Classification: EXPANDED_ACCESS

Brief Summary

To provide treatment access to patients with PFIC in the US who have pruritus and elevated serum bile acids and who are not able to enroll in A4250-008 (PEDFIC2) for the following reasons: 1) Do not meet eligibility criteria for PEDFIC 2; 2) Are not able to get to a PEDFIC 2 site for geographical reasons, and 3) Do meet the eligibility criteria for PEDFIC 2 after recruitment has been completed

Detailed Description

Eligible patients will be enrolled into this expanded-access program and treated with an oral dose of 120 μg/kg/day of odevixibat and evaluated on an ongoing basis.

Conditions

Progressive Familial Intrahepatic Cholestasis

Interventions

Odevixibat

A4250 is a small molecule and selective inhibitor of IBAT

Intervention Type: DRUG

Other Intervention Names

A4250

Eligibility Criteria

Inclusion Criteria

1. A male or female patient of any age, with a clinical diagnosis of PFIC, and with a body weight ≥5 kg at Screening visit

2. Patient must have a clinical diagnosis of PFIC

3. Patient must have clinically confirmed pruritus

4. Patient must have elevated serum bile acid levels, specifically measured to be ≥2 × the upper limit of normal (ULN) prior to start of medication

5. Patient and/or legal guardian must sign informed consent (and assent) as appropriate. Patients who turn 18 years of age (or legal age per country) during

Exclusion Criteria

1. Patient is expected to have a liver transplant within 6 months of Screening

2. Decompensated liver disease, coagulopathy, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

3. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K intravenously, and if INR is ≤1.4 at resampling the patient may be started on program medication)

4. Serum ALT >10 × ULN at Screening

5. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

6. Total bilirubin >10 × ULN at Screening

7. Any patient who is pregnant, lactating, or planning to get pregnant

8. Patients who qualify for enrollment in other Phase 2 or Phase 3 trials intended to support marketing approval in PFIC

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Albireo

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ipsen Medical Director

Role: STUDY_DIRECTOR

Ipsen

Locations

Albireo Pharma Inc.

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

A4250-014

Identifier Type: -

Identifier Source: org_study_id